Core pharmacology: Classic psychedelics are agonists at serotonin receptors, most critically the 5-HT2A subtype. A signaling-dissection study using the selective 5-HT2A agonist DOI showed that receptor activation phosphorylates JAK2, driving both STAT3 Tyr705 phosphorylation and ERK1/2 activation through a PLCΞ²βPKCΞ²βRas axis, with MEK1/2 (U0126, 25 Β΅M) and JAK2 (AG490, 30 Β΅M) inhibition fully blocking downstream effects while PI3K-AKT was activated but not required . This illustrates that 5-HT2A is a pleiotropic G-protein-coupled receptor engaging multiple transduction cascades beyond canonical Gq/PLC.
Broader serotonergic context: Serotonin signaling varies widely by receptor subtype: 5-HT2C receptors tonically inhibit nigrostriatal dopaminergic activity, since 5-HT2C-null mice show elevated substantia nigra dopaminergic firing and striatal dopamine , and 5-HT2A vs 5-HT2C exert opposing control over psychostimulant-induced dopamine output in VTA and nucleus accumbens . Serotonin also stimulates microglial exosome secretion (~4.8-fold IDE release in BV-2 cells at 25 Β΅M 5-HT) .
Epistemic limits: The supplied evidence covers serotonergic receptor signaling broadly but no source directly characterizes psychedelic drugs' subjective or therapeutic neural mechanisms (e.g., cortical glutamate release, neuroplasticity, entropic brain effects). Those central claims are therefore unresolved here; the clinical trials listed (psilocybin in AUD/OCD, LSD dose-ranging, SERT inhibition on LSD response ) address safety and mechanism indirectly.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.